Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

详细信息    查看全文

• 作者：Young-In Yoon ; Shin Hwang ; Young-Joo Lee ; Ki-Hun Kim…
• 关键词：Resection ; Recurrence ; Mixed tumor ; Combined tumor ; Stem cell feature
• 刊名：Journal of Gastrointestinal Surgery
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：20
• 期：2
• 页码：411-420
• 全文大小：4,874 KB
• 参考文献：1.Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol 1949;25:647–655.PubMedCentral PubMed
  2.Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 1985;55:124–135.CrossRef PubMed
  3.Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma. J Gastroenterol Hepatol 2010;25:1485–1492.CrossRef PubMed
  4.Theise ND, Park YN, Nakanuma Y. Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC; 2010:225–227.
  5.Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro M. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol 1996;11:758–764.CrossRef PubMed
  6.Theise ND, Yao JL, Harada K, Hytiroglou P, Portmann B, Thung SN, et al. Hepatic “stem cell” malignancies in adults: Four cases. Histopathology 2003;43:263–271.CrossRef PubMed
  7.Fujii H, Zhu XG, Matsumoto T, Inagaki M, Tokusashi Y, Miyokawa N, et al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol 2000;31:1011–1017.CrossRef PubMed
  8.Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanché H, Franco D, et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol 2004;41:292–298.CrossRef PubMed
  9.Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003;33:283–287.CrossRef PubMed
  10.Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, III, eds. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
  11.Chu KJ, Lu CD, Dong H, Fu XH, Zhang HW, Yao XP. Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma: clinicopathological and prognostic analysis of 390 cases. Eur J Gastroenterol Hepatol 2014;26:192–199.CrossRef PubMed
  12.Ikeda H, Harada K, Sato Y, Sasaki M, Yoneda N, Kitamura S, et al. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Am J Clin Pathol 2013;140:329–340.CrossRef PubMed
  13.Lee CH, Hsieh SY, Chang CJ, Lin YJ. Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. J Gastroenterol Hepatol 2013;28:122–127.CrossRef PubMed
  14.Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol 2009;16:623–629.CrossRef PubMed
  15.Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, et al. The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J Gastrointest Surg 2015;19:1281–1290.CrossRef PubMed
  16.Hwang S, Lee YJ, Song GW, Park KM, Kim KH, Ahn CS, et al. Prognostic impact of tumor growth type on 7th AJCC staging system for intrahepatic cholangiocarcinoma: a single-center experience of 659 cases. J Gastrointest Surg 2015;19:1291–1304.CrossRef PubMed
  17.Hwang S, Ha TY, Song GW, Jung DH, Ahn CS, Moon DB, et al. Quantified risk assessment for major hepatectomy via the indocyanine green clearance rate and liver volumetry combined with standard liver volume. J Gastrointest Surg 2015;19:1305–1314.CrossRef PubMed
  18.Kim JH, Yoon HK, Ko GY, Gwon DI, Jang CS, Song HY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology 2010;255:270–277.CrossRef PubMed
  19.Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg 2006;13:537–542.CrossRef PubMed
  20.Lee JH, Chung GE, Yu SJ, Hwang SY, Kim JS, Kim HY, et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol 2011;45:69–75.PubMed
  21.Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, et al. Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg 2006;10:987–998.CrossRef PubMed
  22.Park YH, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, et al. Long-term outcome of liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma. Transplant Proc 2013;45:3038-3040.CrossRef PubMed
  23.Kojiro M. Pathomorphology of advanced hepatocellular carcinoma. In: Tobe T, Kameda H, Okudaira M et al., eds. Primary Liver Cancer in Japan. Tokyo: Springer-Verlag, 1992.
  24.Alison MR. Liver stem cells: implications for hepatocarcinogenesis. Stem Cell Rev 2005;1:253–260.CrossRef PubMed
  25.Robrechts C, De Vos R, Van den Heuvel M, Van Cutsem E, Van Damme B, Desmet V, et al. Primary liver tumor of intermediate (hepatocyte-bile duct cell) phenotype: a progenitor cell tumour? Liver 1998;18:288–293.CrossRef PubMed
  26.Shiraishi M, Takushi Y, Simoji H, Oshiro T, Shinzato S, Tanigawa N, et al. Combined hepatocellular and cholangiocellular carcinoma in a non-cirrhotic liver. J Gastroenterol 1998;33:593–596.CrossRef PubMed
  27.Zhang F, Chen XP, Zhang W, Dong HH, Xiang S, Zhang WG, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 2008;52:224–232.CrossRef PubMed
  28.Fujii T, Zen Y, Harada K, Niwa H, Masuda S, Kaizaki Y, et al. Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma–human and cell culture study. Hum Pathol 2008;39:1185–1196.CrossRef PubMed
  29.Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 2013;37:496-505.CrossRef PubMed
  30.Kim H, Park C, Han KH, Choi J, Kim YB, Kim JK, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004;40:298–304.CrossRef PubMed
  31.De Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012;56 (Suppl 1):S75–S87.CrossRef PubMed
  32.Liu L, Miao R, Yang H, Lu X, Zhao Y, Mao Y, et al. Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. Am J Surg 2011; 203:741–750.CrossRef PubMed
  33.Li M, Li J, Li P, Li H, Su T, Zhu R, et al. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol 2012;27:1561–1568.CrossRef PubMed
  34.Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-A nationwide cohort study. Gastroenterology 2014;147:143-151.
  35.Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014;147:152-161.CrossRef PubMed
  36.Garancini M, Goffredo P, Pagni F, Romano F, Roman S, Sosa JA, et al. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transpl 2014;20:952-959.CrossRef PubMed
  37.Shetty AS, Fowler KJ, Brunt EM, Agarwal S, Narra VR, Menias CO. Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging 2014;39:310-322.CrossRef PubMed
  
• 作者单位：Young-In Yoon (1)
  Shin Hwang (1)
  Young-Joo Lee (1)
  Ki-Hun Kim (1)
  Chul-Soo Ahn (1)
  Deok-Bog Moon (1)
  Tae-Yong Ha (1)
  Gi-Won Song (1)
  Dong-Hwan Jung (1)
  Jong-Woo Lee (1)
  Seung-Mo Hong (2)
  Eun Sil Yu (2)
  Sung-Gyu Lee (1)
  
  1. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea
  2. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  
• 刊物主题：Surgery; Gastroenterology;
• 出版者：Springer US
• ISSN：1873-4626

文摘

Introduction Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is rare. This study investigated the clinicopathological features of cHCC-CC and compared the postresection survival outcomes of cHCC-CC, hepatocellular carcinoma (HCC), and intrahepatic cholangiocarcinoma (IHC).